Spots Global Cancer Trial Database for her2 negative
Every month we try and update this database with for her2 negative cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients | NCT02511639 | Breast Cancer M... | Everolimus Aromatase Inhib... | 18 Years - | Istituto Oncologico Veneto IRCCS | |
| A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors | NCT04991480 | Advanced Cancer Metastatic Canc... Breast Cancer | ART4215 Talazoparib Niraparib | 18 Years - | Artios Pharma Ltd | |
| Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients | NCT02625935 | Breast Cancer | - | NanoString Technologies, Inc. | ||
| Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors | NCT02028507 | Metastatic Brea... | Palbociclib Capecitabine Exemestane Fulvestrant | 18 Years - | Spanish Breast Cancer Research Group | |
| REaCT-vascular Access Her2 Negative Vascular Access Strategies for (Neo) Adjuvant Breast Cancer Treatment Without Trastuzumab | NCT02688998 | Breast Cancer Cancer | venous access P... | 19 Years - | Ottawa Hospital Research Institute | |
| Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer | NCT05095207 | Breast Cancer Metastasis | Abemaciclib Bicalutamide | 18 Years - 90 Years | Icahn School of Medicine at Mount Sinai | |
| Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer | NCT01495247 | Inoperable Loca... Metastatic Brea... | BEZ235 Paclitaxel | 18 Years - | Novartis | |
| A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer | NCT00887536 | Breast Cancer | bevacizumab docetaxel doxorubicin cyclophosphamid... pegfilgrastim | 18 Years - 70 Years | NSABP Foundation Inc | |
| PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY | NCT03423199 | Breast Neoplasm... | Palbociclib Placebo Tamoxifen Goserelin | 18 Years - | National Cancer Center, Japan | |
| 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer | NCT01626222 | Metastatic Brea... | Exemestane Everolimus (RAD... | 18 Years - | Novartis | |
| To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy | NCT02549430 | Breast Cancer | Palbociclib Anastrozole Letrozole Exemestane Fulvestrant | 18 Years - | Fondazione Sandro Pitigliani | |
| Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC | NCT04565054 | Breast Cancer F... | Abemaciclib 50 ... | 18 Years - | West German Study Group | |
| A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors | NCT04991480 | Advanced Cancer Metastatic Canc... Breast Cancer | ART4215 Talazoparib Niraparib | 18 Years - | Artios Pharma Ltd | |
| BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer | NCT01288092 | Metastatic Brea... | BEZ235 | 18 Years - | Novartis | |
| Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer | NCT02810743 | Breast Cancer | ddAC-CP-Olapari... ddAC-mini CTC | 18 Years - 65 Years | The Netherlands Cancer Institute | |
| Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC | NCT03952325 | Breast Cancer | Tesetaxel Tesetaxel Tesetaxel Nivolumab Pembrolizumab Atezolizumab Tesetaxel | 18 Years - | Odonate Therapeutics, Inc. | |
| A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | NCT03653507 | Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... | zolbetuximab oxaliplatin capecitabine placebo | 18 Years - | Astellas Pharma Inc | |
| Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy | NCT03220178 | Breast Neoplasm | Palbociclib Fulvestrant Anastrozole Letrozole Exemestane | 18 Years - | Palleos Healthcare GmbH | |
| Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer | NCT05025735 | Metastatic Brea... HER2-negative B... | Dapagliflozin 1... | 18 Years - 65 Years | Saint Luke's Health System | |
| A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer | NCT05080842 | Breast Cancer | AC682 | 18 Years - | Accutar Biotechnology Inc | |
| Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer | NCT05025735 | Metastatic Brea... HER2-negative B... | Dapagliflozin 1... | 18 Years - 65 Years | Saint Luke's Health System | |
| Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer | NCT00958971 | Metastatic Brea... | TKI258 | 18 Years - | Novartis | |
| Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer | NCT01891227 | Breast Cancer | Capecitabine Bendamustine | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC) | NCT02688803 | Breast Cancer | Dose dense AC-P Dose dense AC FEC-D | 18 Years - | Ottawa Hospital Research Institute | |
| A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. | NCT06247995 | Breast Cancer | [68Ga]Ga-NeoB [177Lu]Lu-NeoB Capecitabine | 18 Years - | Novartis | |
| 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer | NCT01626222 | Metastatic Brea... | Exemestane Everolimus (RAD... | 18 Years - | Novartis | |
| Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer | NCT01622361 | Breast Cancer | Adriamycin+Cycl... GnRHa with Tamo... | 20 Years - | Asan Medical Center | |
| A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer | NCT01421472 | ER Positive, He... Triple Negative... | MM-121 Paclitaxel | 18 Years - | Merrimack Pharmaceuticals | |
| A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | NCT04577963 | Triple Negative... Endometrial Can... Solid Tumor, Un... Colorectal Canc... | Fruquintinib Tislelizumab | 18 Years - | Hutchmed | |
| Nab-paclitaxel Dose Schedual for HER-2 Negative Advanced Breast Cancer | NCT04192331 | Breast Cancer | nab-paclitaxel ... nab-paclitaxel ... | 18 Years - | Peking University Cancer Hospital & Institute | |
| A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature Assay | NCT01899079 | Breast Cancer | - | NanoString Technologies, Inc. | ||
| Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC | NCT01913067 | Brain Metastasi... Breast Cancer Non Small Cell ... | Cabazitaxel Contrast-enhanc... | 18 Years - | Jules Bordet Institute | |
| A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. | NCT06247995 | Breast Cancer | [68Ga]Ga-NeoB [177Lu]Lu-NeoB Capecitabine | 18 Years - | Novartis | |
| Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer | NCT02810743 | Breast Cancer | ddAC-CP-Olapari... ddAC-mini CTC | 18 Years - 65 Years | The Netherlands Cancer Institute | |
| Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients | NCT02383030 | Metastatic Brea... | Fulvestrant | 18 Years - | Consorzio Oncotech | |
| A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) | NCT01740427 | Breast Neoplasm... | PD-0332991 Letrozole Placebo Letrozole | 18 Years - | Pfizer | |
| Maintenance Bevacizumab or Observation After Taxane Based First Line Chemotherapy In Metastatic Breast Cancer | NCT01978977 | Metastatic Brea... | 18 Years - | Hellenic Oncology Research Group | ||
| A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor | NCT03312738 | Advanced Breast... | Everolimus Exemestane Everolimus Plac... | 18 Years - | Novartis | |
| REaCT-vascular Access Her2 Negative Vascular Access Strategies for (Neo) Adjuvant Breast Cancer Treatment Without Trastuzumab | NCT02688998 | Breast Cancer Cancer | venous access P... | 19 Years - | Ottawa Hospital Research Institute | |
| Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer | NCT02651610 | Metastatic Brea... | Bavituximab Taxane | 18 Years - | Peregrine Pharmaceuticals | |
| BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer | NCT01288092 | Metastatic Brea... | BEZ235 | 18 Years - | Novartis | |
| Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients | NCT02625935 | Breast Cancer | - | NanoString Technologies, Inc. | ||
| Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer | NCT03048942 | HER2 Negative M... | Cabazitaxel Paclitaxel | 18 Years - 99 Years | University Hospitals Bristol and Weston NHS Foundation Trust | |
| Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC | NCT04055493 | Breast Cancer F... | Ribociclib 200M... | 18 Years - | West German Study Group | |
| Trastuzumab and Vinorelbine in Advanced Breast Cancer | NCT01185509 | Breast Cancer Metastatic Brea... | trastuzumab vinorelbine | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | NCT04577963 | Triple Negative... Endometrial Can... Solid Tumor, Un... Colorectal Canc... | Fruquintinib Tislelizumab | 18 Years - | Hutchmed | |
| Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer | NCT02365805 | Breast Cancer | Epirubicin + Ci... Epirubicin + Ci... Docetaxel + Cic... | 18 Years - | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | |
| A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4] | NCT02297438 | Breast Neoplasm... | Palbociclib Letrozole Placebo Letrozole | 18 Years - 70 Years | Pfizer | |
| Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer | NCT04370522 | Metastatic Brea... | 18 Years - | Spanish Breast Cancer Research Group | ||
| Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer | NCT00580333 | Breast Cancer | cisplatin bevacizumab doxorubicin cyclophosphamid... paclitaxel | 18 Years - | Massachusetts General Hospital | |
| AZD9496 First Time in Patients Ascending Dose Study | NCT02248090 | ER+ HER2- Advan... | AZD9496 AZD9496 | 18 Years - | AstraZeneca | |
| Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients | NCT02511639 | Breast Cancer M... | Everolimus Aromatase Inhib... | 18 Years - | Istituto Oncologico Veneto IRCCS | |
| Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies | NCT02025985 | Ovarian Carcino... Endometrial Car... Cervical Carcin... | Selinexor | 18 Years - | Karyopharm Therapeutics Inc | |
| A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer | NCT01038804 | Breast Cancer | YM155 Docetaxel | 18 Years - | Astellas Pharma Inc | |
| A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1) | NCT03988036 | Breast Cancer | Pembrolizumab Trastuzumab Bio... Pertuzumab | 18 Years - | West German Study Group | |
| Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC | NCT04055493 | Breast Cancer F... | Ribociclib 200M... | 18 Years - | West German Study Group | |
| Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer | NCT03206203 | Triple Negative... Stage IV Breast... HER2 Negative Invasive Breast... | Atezolizumab Carboplatin Laboratory Biom... Quality-of-Life... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor | NCT03312738 | Advanced Breast... | Everolimus Exemestane Everolimus Plac... | 18 Years - | Novartis | |
| Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer | NCT00636441 | Early-Stage Bre... | Doxorubicin/Cyc... | 18 Years - | Duke University | |
| A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4] | NCT02297438 | Breast Neoplasm... | Palbociclib Letrozole Placebo Letrozole | 18 Years - 70 Years | Pfizer | |
| The Benefits of Continued Use of Ovarian Function Suppression After 5 Years | NCT06050109 | Breast Cancer F... Endocrine Thera... | OFS continues t... Immunohistochem... | 18 Years - 60 Years | Hubei Cancer Hospital | |
| Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer | NCT01238952 | Advanced Solid ... Metastatic Trip... | NK012 and carbo... | 18 Years - | Nippon Kayaku Co., Ltd. | |
| A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) | NCT05104866 | Breast Cancer | Dato-DXd Capecitabine Gemcitabine Eribulin Vinorelbine | 18 Years - | AstraZeneca | |
| A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer | NCT00887536 | Breast Cancer | bevacizumab docetaxel doxorubicin cyclophosphamid... pegfilgrastim | 18 Years - 70 Years | NSABP Foundation Inc | |
| Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients | NCT02625935 | Breast Cancer | - | NanoString Technologies, Inc. | ||
| Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer | NCT04370522 | Metastatic Brea... | 18 Years - | Spanish Breast Cancer Research Group | ||
| Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients | NCT01885013 | Human Epidermal... | Metformin + Myo... Myocet + Cyclop... | 18 Years - 75 Years | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1) | NCT03988036 | Breast Cancer | Pembrolizumab Trastuzumab Bio... Pertuzumab | 18 Years - | West German Study Group | |
| AZD9496 First Time in Patients Ascending Dose Study | NCT02248090 | ER+ HER2- Advan... | AZD9496 AZD9496 | 18 Years - | AstraZeneca | |
| Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients | NCT01885013 | Human Epidermal... | Metformin + Myo... Myocet + Cyclop... | 18 Years - 75 Years | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC | NCT03952325 | Breast Cancer | Tesetaxel Tesetaxel Tesetaxel Nivolumab Pembrolizumab Atezolizumab Tesetaxel | 18 Years - | Odonate Therapeutics, Inc. | |
| TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer | NCT02586675 | Breast Cancer Breast Cancer -... Breast Cancer -... | Tamoxifen Ribociclib Goserelin | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer | NCT02586675 | Breast Cancer Breast Cancer -... Breast Cancer -... | Tamoxifen Ribociclib Goserelin | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer | NCT01626222 | Metastatic Brea... | Exemestane Everolimus (RAD... | 18 Years - | Novartis | |
| AZD9833 China PK Study | NCT04818632 | ER+, HER2-, Met... | AZD9833 AZD9833 AZD9833 with pa... AZD9833 with ev... | 18 Years - 130 Years | AstraZeneca | |
| Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer | NCT04498520 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Hormone Recepto... Locally Advance... Metastatic Brea... Metastatic Endo... Metastatic Fall... Metastatic HER2... Metastatic Mali... Metastatic Ovar... Metastatic Prim... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Refractory Brea... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IV Uterin... Stage IVA Fallo... Stage IVA Ovari... Stage IVA Prima... Stage IVA Uteri... Stage IVB Fallo... Stage IVB Ovari... Stage IVB Prima... Stage IVB Uteri... | Abexinostat Tos... Fulvestrant Palbociclib | 18 Years - | University of California, San Francisco | |
| Abemaciclib, Palbociclib or Dalpiciclib Combined With Endocrine Therapy as First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer | NCT06344780 | Breast Cancer | 18 Years - 75 Years | Fudan University | ||
| ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA | NCT01730612 | HER2 Negative B... | TF2 - 68 Ga-IMP... | 18 Years - | Nantes University Hospital | |
| Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC | NCT01913067 | Brain Metastasi... Breast Cancer Non Small Cell ... | Cabazitaxel Contrast-enhanc... | 18 Years - | Jules Bordet Institute | |
| A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature Assay | NCT01899079 | Breast Cancer | - | NanoString Technologies, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
